Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer ... drugs do not undergo FDA premarket review for safety, effectiveness, or quality ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues. The San Francisco ...

This comprehensive review of your health history and goals ensures that your weight loss plan, including any medications, such as Zepbound, is realistic and tailored to your needs. The program ...

A review conducted ... reported vision loss after taking semaglutide or tirzepatide, the active ingredients in Ozempic, Wegovy, Mounjaro and Zepbound. Norris at his current weight of 230 pounds ...

State DHS officials say new weight-loss drugs are driving up costs for Pennsylvania’s Medicaid program, likely leading to ...